This study aims to explore the possible pharmacological potential of Linn (Cleomaceae), an annual weed, into therapeutic value-added products. In the present study, we have explored the pharmacological and toxicological profile of coumarinolignoids isolated from for the management of rheumatoid arthritis and related complications in a small animal model. To avoid the biasness during experiments on animals, we have coded the isolated coumarinolignoids as to perform the experimental pharmacological study. was orally administrated (30,100, 300 mg/kg) to animal models of collagen-induced arthritis (CIA), carrageenan-induced acute inflammation, thermal and chemical-induced pain, and Brewer's yeast-induced pyrexia. Oral administration of significantly decreases the arthritis index, arthritis score, and increases the limb withdrawal threshold in the CIA model in experimental rats. The anti-arthritis studies revealed that the anti-inflammatory effect of was associated with inhibition of the production of inflammatory mediators like TNF-, IL-6, IL-17A, MMP-1, MMP-9, Nitric oxide, and C-RP in CIA rat's serum, and also reduced the NFB-p65 expression as evidence of immunohistochemistry in knee joint tissue of CIA rats, in a dose-dependent manner. Further individual experiments related to arthritis-related complications in experimental animals demonstrated the analgesic, anti-inflammatory, and antipyretic potential of in a dose-dependent manner. Further, an acute oral toxicity study concluded that is safe in experimental animals up to 2,000 mg/kg dose. The results of this study suggested that the oral administration of may be a therapeutic candidate for further investigation in the management of rheumatoid arthritis and related complications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/a-1906-1837 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!